Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma.
Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok TS, Yeo W.
Cancer. 2011 Dec 16. doi: 10.1002/cncr.26726. [Epub ahead of print]
Related citations
Clinical outcomes of oncologic gastrointestinal resections in patients with cirrhosis.
Artinyan A, Marshall CL, Balentine CJ, Albo D, Orcutt ST, Awad SS, Berger DH, Anaya DA.
Cancer. 2011 Dec 13. doi: 10.1002/cncr.26682. [Epub ahead of print]
Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
Turley RS, Peng PD, Reddy SK, Barbas AS, Geller DA, Marsh JW, Tsung A, Pawlik TM, Clary BM.
Cancer. 2011 Nov 15. doi: 10.1002/cncr.26650. [Epub ahead of print]
Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K.
Cancer. 2011 Nov 9. doi: 10.1002/cncr.26648. [Epub ahead of print]
Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma.
Price TR, Perkins SM, Sandrasegaran K, Henderson MA, Maluccio MA, Zook JE, Tector AJ, Vianna RM, Johnstone PA, Cardenes HR.
Cancer. 2011 Oct 24. doi: 10.1002/cncr.26404. [Epub ahead of print]
Real-time detection of hepatic micrometastases from pancreatic cancer by intraoperative fluorescence imaging: Preliminary results of a prospective study.
Yokoyama N, Otani T, Hashidate H, Maeda C, Katada T, Sudo N, Manabe S, Ikeno Y, Toyoda A, Katayanagi N.
Cancer. 2012 Jun 1;118(11):2813-9. doi: 10.1002/cncr.26594. Epub 2011 Oct 11.
Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma.
Xie Q, Chen X, Lu F, Zhang T, Hao M, Wang Y, Zhao J, McCrae MA, Zhuang H.
Cancer. 2012 May 1;118(9):2431-42. doi: 10.1002/cncr.26566. Epub 2011 Oct 11.
HIWI is associated with prognosis in patients with hepatocellular carcinoma after curative resection.
Zhao YM, Zhou JM, Wang LR, He HW, Wang XL, Tao ZH, Sun HC, Wu WZ, Fan J, Tang ZY, Wang L.
Cancer. 2012 May 15;118(10):2708-17. doi: 10.1002/cncr.26524. Epub 2011 Oct 11.
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Brouquet A, Overman MJ, Kopetz S, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN.
Cancer. 2011 Oct 1;117(19):4484-92. doi: 10.1002/cncr.26036. Epub 2011 Mar 28.
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.
Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C.
Cancer. 2012 May 1;118(9):2424-30. doi: 10.1002/cncr.26556. Epub 2011 Sep 27.
Postchemotherapy histological analysis of major intrahepatic vessels for reversal of attachment or invasion by colorectal liver metastases.
Tanaka K, Kumamoto T, Nojiri K, Takeda K, Endo I.
Cancer. 2012 May 1;118(9):2443-53. doi: 10.1002/cncr.26563. Epub 2011 Sep 22.
A functional single nucleotide polymorphism at the promoter region of cyclin A2 is associated with increased risk of colon, liver, and lung cancers.
Kim DH, Park SE, Kim M, Ji YI, Kang MY, Jung EH, Ko E, Kim Y, Kim S, Shim YM, Park J.
Cancer. 2011 Sep 1;117(17):4080-91. doi: 10.1002/cncr.25930. Epub 2011 Feb 24.
Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis.
Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, Schefter TE.
Cancer. 2011 Sep 1;117(17):4060-9. doi: 10.1002/cncr.25997. Epub 2011 Mar 22.
Heat shock factor 1 promotes invasion and metastasis of hepatocellular carcinoma in vitro and in vivo.
Fang F, Chang R, Yang L.
Cancer. 2012 Apr 1;118(7):1782-94. doi: 10.1002/cncr.26482. Epub 2011 Aug 25.
National trends in surgical procedures for hepatocellular carcinoma: 1998-2008.
Nathan H, Segev DL, Mayo SC, Choti MA, Cameron AM, Wolfgang CL, Hirose K, Edil BH, Schulick RD, Pawlik TM.
Cancer. 2012 Apr 1;118(7):1838-44. doi: 10.1002/cncr.26501. Epub 2011 Aug 25.
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA.
Cancer. 2011 Aug 1;117(15):3374-82. doi: 10.1002/cncr.25852. Epub 2011 Jan 18.
A clustered ground-glass hepatocyte pattern represents a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery.
Tsai HW, Lin YJ, Lin PW, Wu HC, Hsu KH, Yen CJ, Chan SH, Huang W, Su IJ.
Cancer. 2011 Jul 1;117(13):2951-60. doi: 10.1002/cncr.25837. Epub 2011 Jan 10.
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL.
Cancer. 2012 Jan 1;118(1):147-56. doi: 10.1002/cncr.26255. Epub 2011 Jun 28.
FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo.
Fang F, Yang L, Tao Y, Qin W.
Cancer. 2012 Jan 1;118(1):134-46. doi: 10.1002/cncr.26251. Epub 2011 Jun 28.
AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group.
Farges O, Fuks D, Le Treut YP, Azoulay D, Laurent A, Bachellier P, Nuzzo G, Belghiti J, Pruvot FR, Regimbeau JM.
Cancer. 2011 May 15;117(10):2170-7. doi: 10.1002/cncr.25712. Epub 2010 Nov 29.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on